# Delayed Menarche and Amenorrhea in Ballet Dancers

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1056/NEJM198007033030105</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:16953387">http://nrs.harvard.edu/urn-3:HUL.InstRepos:16953387</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
In our patient, after the initiation of antineoplastic chemotherapy, a precipitous fall in the serum lactate concentration occurred, accompanied by the restoration of a normal L/P ratio and correction of metabolic acidosis (Fig. 1). Rapid involution of Hodgkin's disease occurred simultaneously, evidenced by complete disappearance of the parotid swellings and submandibular lymphadenopathy and a marked diminution in the liver size. This therapeutic response suggests that the lactic acidosis could be attributed directly to the Hodgkin's disease.

Although administration of massive amounts of intravenous bicarbonate may be imperative in the initial treatment of patients with severe lactic acidosis, this therapy is not without hazards since lethal hyperosmolality has been observed.1,14 In addition, recent studies in animals have also provided evidence suggesting detrimental effects of bicarbonate in the treatment of experimentally induced lactic acidosis.15

The evidence reported here suggests that when lactic acidosis is associated with Hodgkin's disease, the successful reversal of this potentially lethal metabolic derangement may depend on the prudent institution of effective antineoplastic chemotherapy rather than on bicarbonate administration alone. Chemotherapy may have importance in the treatment of patients with lactic acidosis in other neoplasms that are susceptible to specific therapy.4,4,5

References


DELAYED MENARCHE AND AMENORRHEA IN BALLET DANCERS

Rose E. Frisch, Ph.D., Grace Vyshak, Ph.D., and Larry Vincent, M.D.

Young female ballet dancers attending professional schools or dancing in companies in which thinness is much admired restrict their food intake and are highly active. The unusual eating habits and levels of activity of some of these dancers have been related to lack of menstrual cycles. Amenorrhea and late menarche among girls and women with average activity levels are associated with undernutrition and weight loss in the range of 10 to 15 per cent of the normal weight for height; such weight loss apparently reduces the fat/lean ratio to less than a critical level. We report here on 89 young ballet dancers among whom there was a high incidence of primary amenorrhea, secondary amenorrhea, irregular cycles, and delayed menarche — an incidence correlated with excessive thinness.

Subjects and Methods

A questionnaire on age, height, weight, duration of training, age of menarche, and menstrual periodicity was distributed to 89 dancers. The respondents were studying at three professional ballet schools in highly competitive programs: 58 were scholarship students, and 10 were members of a professional apprentice company. Two dancers did not know at what age menarche had begun. Dancers of age 16 years and older who reported "no menarche yet" were classified as having primary amenorrhea; lack of cycles for longer than three consecutive months was classified as secondary amenorrhea. Intervals between menstruations of more than 38 days but less than three months were classified as irregular cycles.

Total body water, expressed as the percent of body weight — a measure of relative fatness — was estimated for each girl from her height and weight. Body leanness may have been underestimated, since it is likely that in dancers, as compared with untrained women or girls, more of the weight is muscle.

Results

The data are summarized in Table 1. Ten per cent (nine) of the group reported primary amenorrhea occurring at 18.5±0.5 years (mean ±S.E.M.); six were older than 18.0 years (one was 19.9 and another 20.6). Twelve per cent (11) of the dancers reported that they had not undergone menarche at 14.3±0.4 years; five were in their 15th year. Fifteen per cent (13) of the group reported secondary amenorrhea, and 30 per cent (27) reported irregular cycles. Thirty-three per cent (29) of the dancers reported regular cycles.

The mean age at menarche reported by 67 of the 69 postmenarcheal dancers was 13.7±0.1 (1.2 S.D.) years, which is significantly later (P<0.001) than the mean ages of 12.8±0.054 and 12.9±0.1 years report-

From the Center for Population Studies, Harvard School of Public Health, Cambridge; the Department of Preventive and Social Medicine, Harvard Medical School, Boston; and the Department of Radiology, St. Vincent's Hospital, New York (address reprint requests to Dr. Frisch at the Center for Population Studies, 9 Bow St., Cambridge, MA 02138).
ed for American girls. Probit analysis could not be used to estimate the mean age of the whole group because of the high percentage of older dancers reporting "no menarche yet"; the data therefore did not conform to a sigmoid curve.

Dancers with amenorrhea and with irregular cycles were significantly leaner than dancers reporting regular cycles (Table 1). The 20 dancers of all ages reporting "no menarche yet" were significantly leaner than the dancers of the three other groups (F = 7.69, P<0.01). As is indicated by their average total body water as per cent of body weight, the weight for height of each of these dancers was below the critical weight for height necessary for menarche or the maintenance of regular cycles in well-nourished women with average activity. Their weights for height are also below the standard termed "underweight" for young women. Even the dancers in the group with regular cycles also were in the very low range of weight for height and relative fatness for their age; however, all but one of them were above the threshold, minimum weights for menarche or maintenance of cycles. Two dancers reporting irregular cycles were in the range of normal fatness for maintaining cycles, demonstrating that the weight is necessary but not sufficient for cycles to occur; emotional or physical stress may override the effect of weight.

The mean height (158.7±1.2 cm) of the 11 dancers reporting "no menarche yet" at a mean age of 14.3±0.4 years (Table 1) was similar to the height (158.5±0.5 cm) of well-nourished non-dancers at menarche at 12.9±0.1 years, but the mean weight of the dancers (42.0±0.9 kg) was significantly less than that of the well-fed girls (47.8±0.5 kg) (P<0.001).7

**DISCUSSION**

The relatively late mean age at menarche and the delayed menarche of the dancers may show that late maturers choose to be ballet dancers or that the hard training and low food intake typical of ballet dancers cause excessive thinness that delays puberty.1 The fact that most of the dancers began their training at young ages (Table 1), and the high incidence of secondary amenorrhea and irregular cycles suggest that the latter factors — hard training and low intake — contribute strongly to this phenomenon.

Warren has reported a late mean age of menarche, 15.4 years, for 13 selected young ballet dancers, in association with thinness and the energy drain of hard training.9 A sample group of women runners also had a relatively late age at menarche and a high incidence of amenorrhea, the latter positively correlated with the number of miles run per week.10 Finally, high-school and college athletes have a statistically significant later age at menarche than do nonathletes.11

The occurrence of menarche after an injury preventing dancing supports the hypothesis that a change in fat/lean ratio12 and the accompanying changes in metabolic12 and hormonal13 characteristics of hard physical exercise may be involved in the delay of menarche and menstrual disturbances in these ballet dancers. A change in the ratio may also result from an increase in leanness, in addition to a decrease in fatness, without weight loss or even with weight gain, as found in many athletes (Frisch RE, Welbergen A, McArthur JW, Albright T, Bullen B, Witschi J, Reed RB: unpublished data).14

We are indebted to E. L. Lowenkopf, M.D., for his assistance in collecting the data.

**REFERENCES**

3. Frisch RE, McArthur JW. Menstrual cycles: fatness as a determinant of

---

**Table 1. Characteristics of 89 Ballet Dancers Reporting Lack of Menstrual Cycles, Irregular Cycles, and Regular Cycles.**

<table>
<thead>
<tr>
<th>Group Classification (No. in Group)</th>
<th>Age at Time of Study</th>
<th>Age at Menarche</th>
<th>Age at Start of Training</th>
<th>Height (cm)</th>
<th>Weight (kg/Lb)</th>
<th>Estimated BW/BMI†</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary amenorrhea — age &gt;16 (9)</td>
<td>18.4±0.5</td>
<td>Not yet</td>
<td>8.4±0.9</td>
<td>163.7±1.3</td>
<td>43.5±0.5 $\ddagger$</td>
<td>59.5±0.6 $\dagger$</td>
<td></td>
</tr>
<tr>
<td>No amenorrhea yet — age &lt;16 (11)</td>
<td>14.3±0.4</td>
<td>Not yet</td>
<td>8.7±0.5</td>
<td>158.7±1.2</td>
<td>42.0±0.9 $\dagger$</td>
<td>58.9±0.4 $\dagger$</td>
<td></td>
</tr>
<tr>
<td>Secondary amenorrhea (13)</td>
<td>17.9±0.4</td>
<td>14.3±0.4 $\dagger$</td>
<td>7.8±0.4</td>
<td>162.7±1.4</td>
<td>44.9±1.6 (98.8±3.5)</td>
<td>58.3±0.7 $\dagger$</td>
<td></td>
</tr>
<tr>
<td>Irregular cycles (27)</td>
<td>16.7±0.3</td>
<td>13.9±0.3 $\dagger$</td>
<td></td>
<td>7.2±0.7</td>
<td>163.5±0.9</td>
<td>45.9±0.7 (101.0±1.5)</td>
<td>57.7±0.4 $\dagger$</td>
</tr>
<tr>
<td>Regular cycles (29)</td>
<td>17.0±0.4</td>
<td>13.3±0.2</td>
<td></td>
<td>7.4±0.4</td>
<td>162.0±1.0</td>
<td>47.0±0.8 (103.4±1.8)</td>
<td>56.3±0.5 $\dagger$</td>
</tr>
<tr>
<td>All subjects (89)</td>
<td>16.8±0.2</td>
<td>13.4±0.3 $\dagger$</td>
<td></td>
<td>7.4±0.3</td>
<td>163.2±0.5</td>
<td>45.5±0.5 (100.1±1.1)</td>
<td>57.6±0.3 $\dagger$</td>
</tr>
</tbody>
</table>

*Values are expressed as mean ±S.E.M.
†Total body water expressed as percentage of body weight. Fat/body weight per cent = 100 - (per cent lean)
$\dagger$Significantly different from group with regular cycles, P<0.05.
$\ddagger$Significantly different from group with irregular cycles, P<0.01.
$\ddagger$Significantly different from group with regular cycles, P<0.01.
$\dagger$Age for one subject was not known.
minimum weight for height necessary for their maintenance or onset.
dysfunction in secondary amenorrhea associated with simple
follow-up of patients with psychogenic amenorrhea. In: Zichella L,
Pancheri P, eds. Psychoneuroendocrinology in reproduction. Amster-
development and growth in American girls: the statistics of menarche.
7. Frisch RE, Revelle R. Height and weight at menarche and a hypothesis
9. Warren MP. The effects of exercise on pubertal progression and repro-
10. Feicht CB, Johnson TS, Martin BJ, et al. Secondary amenorrhea in
11. Malina RM, Spirduso WW, Tate C, Baylor AM. Age at menarche and
selected menstrual characteristics in athletes at different competitive
and insulin binding to monocytes after physical training. N Engl J Med.
13. Sutton JR, Coleman MJ, Casey J, Lazarus L. Androgen responses dur-
Human body composition: approaches and applications. Vol. VII. Ox-

Frequently, however, they progress to a more serious clinical stage characterized by dysarthria, ataxia, seizures, dementia, or coma. The definitive diagnosis of this syndrome is usually established at autopsy by the histopathological finding in the brain tissue of demyelination accompanied by multifocal necrosis, astrocytosis, and occasionally dystrophic calcifications.6-9

The cerebrospinal fluid of 39 patients who had acute lymphoblastic leukemia and had been treated with cranial irradiation and intrathecal methotrexate was examined for the presence of myelin basic protein, a specific component of the myelin sheath and an indicator of demyelination.10,11 Increased levels of this protein (>4 ng per milliliter) were detected in all seven patients with clinically overt necrotizing leuko-
ecephalopathy. Furthermore, serial determinations in two patients demonstrated that increasing levels of myelin basic protein in the cerebrospinal fluid correlated with disease progression and likewise returned to normal with resolution of clinical symptomatology.

**Methods**

**Patients**

Cerebrospinal fluid was obtained from 39 patients who had acute lymphoblastic leukemia and were three to 20 years of age. The patients were categorized into four groups.

Group I consisted of seven patients with clinically overt signs and symptoms of necrotizing leukoencephalopathy. All had received cranial irradiation (2400 rads) and multiple doses of intrathecal methotrexate for central-nervous-system prophylaxis. Two patients had received additional therapy for meningeal leukemia before the onset of leukoencephalopathy. The diagnosis of leukoencephalopa-
thy was made on the basis of characteristic clinical findings12,13 and the exclusion of other possible causes of encephalopathy or demyelination.

Group II consisted of 21 patients who had previously completed central-nervous-system prophylaxis consisting of cranial irradiation (2400 rads) and multiple doses of intrathecal methotrexate. Cerebrospinal-fluid samples were obtained from one month to 6½ years after completion of central-nervous-system prophylaxis. Six-
teen of the 21 patients were still receiving systemic maintenance chemotherapy without any intrathecal or intravenous metho-
trexate.

Group III consisted of seven patients undergoing central-nervous-system prophylaxis. Cerebrospinal fluid was obtained from these patients during the time of prophylactic treatment, which consisted of cranial irradiation and intrathecal methotrexate. All these patients were being treated with cranial irradiation and had received at least two doses of intrathecal methotrexate when sam-
ple of cerebrospinal fluid were obtained.

Group IV consisted of four patients with meningeal leukemia. These patients were receiving therapy for active meningeal leukemia when cerebrospinal-fluid samples were obtained. All four had received cranial irradiation and intrathecal methotrexate as prophylaxis and were being treated for meningeal leukemia with intralumbar or intraventricular methotrexate (two patients). All had a leukemic pleocytosis in the cerebrospinal fluid at the time of study.

**Collection of Cerebrospinal Fluid**

Cerebrospinal fluid (1 ml) was obtained from patients by lumbar puncture or Ommaya reservoir sampling either at the time of

---

**LEUKOENCEPHALOPATHY AND ELEVATED LEVELS OF MYELIN BASIC PROTEIN IN THE CEREBROSPINAL FLUID OF PATIENTS WITH ACUTE LYMPHOBlastic LEUKEMIA**

**DIAMON GANGJI, M.D., GREGORY H. REAMAN, M.D., STEPHEN R. COHEN, PH.D., W. ARCHIE BLEYER, M.D., AND DAVID G. POPLACK, M.D.**

As the survival of patients with acute lymphoblastic leukemia has improved, increased attention has focused on the potential toxicity and adverse long-term sequelae of antileukemic therapy. In particular, there is considerable interest in the toxic effects on the central nervous system that may result from therapy to treat or prevent meningeal leukemia. A wide range of neurotoxicities have been described, the most serious of which is the syndrome of necrotizing leukoencephalopathy associated with cranial irradiation and the administration of methot-
exate.1-5 Clinically, patients with this delayed form of neurotoxicity present with symptoms such as poor performance in school, forgetfulness, and confusion.

From the Pediatric Oncology Branch, National Cancer Institute; the Department of Neurochemistry, Johns Hopkins University, Baltimore; and the departments of Pediatrics and Radiation Oncology, University of Washington, Seattle. Address reprint requests to Dr. Gangji at Bolg 10, Room 3B103, National Cancer Institute, Bethesda, MD 20050.

---

Dr. Gangji is a Fellow of the Rose et Jean Huguet Cancer Research Foundation; Dr. Bleyer is a Scholar of the Leukemia Society of America; Dr. Cohen is a recipient of a grant (14167) from the National Institutes of Health.